Publications by authors named "Edwin Anderson"

Claim this Profile
F
Features predicting colchicine efficacy in treatment of children with undefined systemic autoinflammatory disease: A retrospective cohort study.
Mariana Correia Marques, Buğra Han Egeli, Holly Wobma, Claudio Ribeiro, Edwin Anderson

Eur J Rheumatol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Process Flow Disruption Analysis to Guide Quality Improvement.
Douglas P Slakey, Gökçe Sargut, Nicole E Glowacki, Parisa Y Katoozian, William J Baylis, Edwin J Anderson

J Am Coll Surg· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbiome is not linked to clinical disease severity of familial Mediterranean fever in an international cohort of children.
Seza Ozen, Holly L Lutz, Vanessa M Rivera, Andreas Reiff, Ezgi Deniz Batu, Edwin Anderson

Clin Exp Rheumatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying international organization for standards 9001 to create an effective surgical quality committee.
Douglas P Slakey, James S George, Edwin Anderson, Donna Willeumier, Kelly Guglielmi

Am J Surg· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing Public-Private Partnerships in Plant Pathology Extension: Case Studies and Opportunities in the United States.
Samuel G Markell, Gregory L Tylka, Edwin J Anderson, H Peter van Esse

Annu Rev Phytopathol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
Flor M Munoz, Evan J Anderson, David I Bernstein, Christopher J Harrison, Barbara Pahud, Edwin Anderson

Vaccine· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Pornthep Chanthavanich, Edwin Anderson, Phirangkul Kerdpanich, Michael Bulitta, Niranjan Kanesa-Thasan

Pediatr Infect Dis J· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Edwin Anderson

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Hatice Ezgi Baris, Edwin Anderson, Betul Sozeri, Fatma Dedeoglu

Clin Rheumatol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).
Sharon E Frey, Kathleen Lottenbach, Irene Graham, Edwin Anderson, Kanwaldeep Bajwa

Vaccine· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.
Mark J Mulligan, Jack T Stapleton, Wendy A Keitel, Sharon E Frey, Wilbur H Chen, Edwin Anderson

Vaccine· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Lisa A Jackson, Sharon E Frey, Hana M El Sahly, Mark J Mulligan, Patricia L Winokur, Evan J Anderson, Edwin L Anderson

Vaccine· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Sharon E Frey, Anna Wald, Srilatha Edupuganti, Lisa A Jackson, Jack T Stapleton, Edwin L Anderson

Vaccine· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.
Natasha B Halasa, Michael A Gerber, Andrea A Berry, Edwin L Anderson, Patricia Winokur

J Pediatric Infect Dis Soc· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Lisa A Jackson, James D Campbell, Sharon E Frey, Kathryn M Edwards, Wendy A Keitel, Edwin L Anderson

JAMA· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
Sharon E Frey, David I Bernstein, Rebecca C Brady, Wendy A Keitel, Hana El Sahly, Edwin L Anderson

Vaccine· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.
Mark J Mulligan, David I Bernstein, Sharon Frey, Patricia Winokur, Nadine Rouphael, Edwin Anderson

Open Forum Infect Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended solutions to the barriers to immunization in children and adults.
Edwin L Anderson

Mo Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Robert B Belshe, Sharon E Frey, Irene L Graham, Edwin L Anderson, Lisa A Jackson

JAMA· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Center for Vaccine Development More Important Now More Than Ever.
Edwin L Anderson

Mo Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.
Daniel F Hoft, Elizabeth Babusis, Shewangizaw Worku, Charles T Spencer, Kathleen Lottenbach, Edwin L Anderson

J Infect Dis· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bacteriology of blood, wound, and sputum cultures from non-US casualties treated in a combat support hospital in Iraq.
Kimberly A Moran, Clinton K Murray, Edwin L Anderson

Infect Control Hosp Epidemiol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.
Mark G Kortepeter, James W Martin, Janice M Rusnak, Theodore J Cieslak, Kelly L Warfield, Edwin L Anderson

Emerg Infect Dis· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
Robert B Belshe, Frances K Newman, Edwin L Anderson, Peter F Wright, Ruth A Karron

J Infect Dis· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
Robert B Belshe, Frances K Newman, Theodore F Tsai, Ruth A Karron, Keith Reisinger, Edwin Anderson

J Infect Dis· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis